Download as PDF
74317
Federal Register / Vol. 72, No. 249 / Monday, December 31, 2007 / Notices
AIDS Program (codified under Title
XXVI of the Public Health Service Act)
would be required to report financial
data to HRSA at the beginning and end
of their grant cycle.
All parts of the Ryan White HIV/AIDS
Program specify HRSA’s responsibilities
in the administration of grant funds.
Accurate allocation and expenditure
records of the grantees receiving Ryan
White HIV/AIDS Program funding are
critical to the implementation of the
legislation and thus are necessary for
HRSA to fulfill its responsibilities.
The new law changes how Ryan
White HIV/AIDS Program funds can be
used, with an emphasis on providing
life-saving and life-extending services
for people living with HIV/AIDS across
this country. More money will be spent
on direct health care for Ryan White
HIV/AIDS Program clients. Under the
new law, unless they receive a waiver,
grantees receiving funds under Parts A,
B, and C must spend at least 75 percent
of funds on ‘‘core medical services’’ and
can spend no more than 5 percent or 3
million dollars (whichever is smaller)
on clinical quality management. Under
Parts A–D, there is also a 10 percent
spending cap on grantee administration.
The forms would require grantees to
report on how funds are allocated and
spent on core and non-core services,
and on various program components,
such as administration, planning and
evaluation, and quality management.
The two forms are identical in the types
of information they collect. However,
the first report would track the
allocation of their award at the
Number of
grantee
respondents
Program under which grantee is funded
Part
Part
Part
Part
Part
Part
Responses
per grantee
beginning of their grant cycle and the
second report would track actual
expenditures (including carryover
dollars) at the end of their grant cycle.
The primary purposes of these forms
are to: (1) provide information on the
number of grant dollars spent on various
services and program components, and
(2) oversee compliance with the intent
of congressional appropriations in a
timely manner. In addition to meeting
the goal of accountability to the
Congress, clients, advocacy groups, and
the general public, information
collected on these reports is critical for
HRSA, State, and local grantees, and
individual providers to evaluate the
effectiveness of these programs.
The response burden for grantees is
estimated as:
Total
responses
Hours to
complete each
form
Total hours
A ...................................................................................
B ...................................................................................
A MAI ...........................................................................
B MAI ...........................................................................
C ...................................................................................
D ...................................................................................
56
59
56
59
361
90
2
2
2
2
2
2
112
118
112
118
722
180
8
12
4
4
7
7
896
1416
448
472
5054
1260
Total ..............................................................................
681
........................
1,362
........................
9,546
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to
the desk officer for HRSA, either by
email to
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974. Please direct all
correspondence to the ‘‘attention of the
desk officer for HRSA.’’
Dated: December 20, 2007.
Alexandra Huttinger,
Acting Director, Division of Policy Review
and Coordination.
[FR Doc. E7–25332 Filed 12–28–07; 8:45 am]
collection requests under review by the
Office of Management and Budget
(OMB), in compliance with the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35). To request a copy of
the clearance requests submitted to
OMB for review, call the HRSA Reports
Clearance Office on (301) 443–1129.
The following request has been
submitted to the Office of Management
and Budget for review under the
Paperwork Reduction Act of 1995:
Proposed Project: HRSA AIDS Drug
Assistance Program Quarterly Report—
(OMB No. 0915–0295): Revision
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
sroberts on PROD1PC70 with NOTICES
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources
and Services Administration (HRSA)
publishes abstracts of information
VerDate Aug<31>2005
20:08 Dec 28, 2007
Jkt 214001
HRSA’s AIDS Drug Assistance
Program (ADAP) is funded through Part
B of Title XXVI of the Public Health
Service Act, as amended by the Ryan
White HIV/AIDS Treatment
Modernization Act of 2006 (The Ryan
White HIV/AIDS Program), which
provides grants to States and Territories.
The ADAP provides medications for the
treatment of HIV disease. Program funds
may also be used to purchase health
insurance for eligible clients or for
services that enhance access, adherence,
and monitoring of drug treatments.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Each of the 50 States, the District of
Columbia, Puerto Rico, and several
Territories receive ADAP grants. As part
of the funding requirements, ADAP
grantees submit quarterly reports that
include information on patients served,
pharmaceuticals prescribed, pricing,
and other sources of support to provide
AIDS medication treatment, eligibility
requirements, cost data, and
coordination with Medicaid. Each
quarterly report requests updates from
programs on number of patients served,
type of pharmaceuticals prescribed, and
prices paid to provide medication. The
first quarterly report of each ADAP
fiscal year (due in July of each year) also
requests information that only changes
annually (e.g., State funding, drug
formulary, eligibility criteria for
enrollment, and cost-saving strategies
including coordinating with Medicaid).
The quarterly report represents the
best method for HRSA to determine how
ADAP grants are being expended and to
provide answers to requests from
Congress and other organizations.
The estimated annual burden is as
follows:
E:\FR\FM\31DEN1.SGM
31DEN1
74318
Federal Register / Vol. 72, No. 249 / Monday, December 31, 2007 / Notices
Number of
respondents
Form
Responses
per respondent
Total
responses
Hours per
response
Total burden
hours
1st Quarterly Report .............................................................
2nd, 3rd, & 4th Quarterly Reports .........................................
57
57
1
3
57
171
3
1.5
171
256.5
Total ..............................................................................
57
........................
228
........................
427.5
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to
the desk officer for HRSA, either by email to OIRA_submission@omb.eop.gov
or by fax to 202–395–6974. Please direct
all correspondence to the ‘‘attention of
the desk officer for HRSA.’’
Dated: December 20, 2007.
Alexandra Huttinger,
Acting Director, Division of Policy Review
and Coordination.
[FR Doc. E7–25336 Filed 12–28–07; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
sroberts on PROD1PC70 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Cancer
Advisory Board.
Open: February 5, 2008, 8:30 a.m. to 4:15
p.m.
Agenda: Program reports and
presentations; Business of the Board.
VerDate Aug<31>2005
20:08 Dec 28, 2007
Jkt 214001
Place: National Cancer Institute, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Closed: February 5, 2008, 4:15 p.m. to 5:30
p.m.
Agenda: Review of grant applications.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Open: February 6, 2008, 8 a.m. to 12 p.m.
Agenda: Program reports and
presentations; Business of the Board.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: http://
deainfo.nci.nih.gov/advisory/ncab.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Dated: December 19, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–6245 Filed 12–28–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of meetings of the
National Advisory Council for Human
Genome Research.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Human Genome Research.
Date: February 11–12, 2008.
Open: February 11, 2008, 8:30 a.m. to 1
p.m.
Agenda: To discuss matters of program
relevance.
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892.
Closed: February 11, 2008, 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892.
Closed: February 12, 2008, 8:30 a.m. to
Adjournment.
E:\FR\FM\31DEN1.SGM
31DEN1

Agencies

[Federal Register Volume 72, Number 249 (Monday, December 31, 2007)]
[Notices]
[Pages 74317-74318]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-25336]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources and Services Administration
(HRSA) publishes abstracts of information collection requests under
review by the Office of Management and Budget (OMB), in compliance with
the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request
a copy of the clearance requests submitted to OMB for review, call the
HRSA Reports Clearance Office on (301) 443-1129.
The following request has been submitted to the Office of
Management and Budget for review under the Paperwork Reduction Act of
1995:
Proposed Project: HRSA AIDS Drug Assistance Program Quarterly Report--
(OMB No. 0915-0295): Revision
HRSA's AIDS Drug Assistance Program (ADAP) is funded through Part B
of Title XXVI of the Public Health Service Act, as amended by the Ryan
White HIV/AIDS Treatment Modernization Act of 2006 (The Ryan White HIV/
AIDS Program), which provides grants to States and Territories. The
ADAP provides medications for the treatment of HIV disease. Program
funds may also be used to purchase health insurance for eligible
clients or for services that enhance access, adherence, and monitoring
of drug treatments.
Each of the 50 States, the District of Columbia, Puerto Rico, and
several Territories receive ADAP grants. As part of the funding
requirements, ADAP grantees submit quarterly reports that include
information on patients served, pharmaceuticals prescribed, pricing,
and other sources of support to provide AIDS medication treatment,
eligibility requirements, cost data, and coordination with Medicaid.
Each quarterly report requests updates from programs on number of
patients served, type of pharmaceuticals prescribed, and prices paid to
provide medication. The first quarterly report of each ADAP fiscal year
(due in July of each year) also requests information that only changes
annually (e.g., State funding, drug formulary, eligibility criteria for
enrollment, and cost-saving strategies including coordinating with
Medicaid).
The quarterly report represents the best method for HRSA to
determine how ADAP grants are being expended and to provide answers to
requests from Congress and other organizations.
The estimated annual burden is as follows:
[[Page 74318]]
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total Hours per Total burden
Form respondents respondent responses response hours
----------------------------------------------------------------------------------------------------------------
1\st\ Quarterly Report.......... 57 1 57 3 171
2\nd\, 3\rd\, & 4\th\ Quarterly 57 3 171 1.5 256.5
Reports........................
-------------------------------------------------------------------------------
Total....................... 57 .............. 228 .............. 427.5
----------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent within 30 days of this notice to
the desk officer for HRSA, either by e-mail to OIRA_
submission@omb.eop.gov or by fax to 202-395-6974. Please direct all
correspondence to the ``attention of the desk officer for HRSA.''
Dated: December 20, 2007.
Alexandra Huttinger,
Acting Director, Division of Policy Review and Coordination.
[FR Doc. E7-25336 Filed 12-28-07; 8:45 am]
BILLING CODE 4165-15-P